Published in Intensive Care Med on October 07, 2008
Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHS) | NCT00625209
Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS. Chest (2010) 1.43
Scientific and clinical challenges in sepsis. Curr Pharm Des (2009) 1.14
Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response. Recent Pat Inflamm Allergy Drug Discov (2009) 1.14
Once is not enough: clinical trials in sepsis. Intensive Care Med (2008) 1.04
Activated protein C in septic shock: a propensity-matched analysis. Crit Care (2011) 0.93
Patient recruitment into a multicenter randomized clinical trial for kidney disease: report of the focal segmental glomerulosclerosis clinical trial (FSGS CT). Clin Transl Sci (2012) 0.92
The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis. Crit Care (2011) 0.89
Current concept of abdominal sepsis: WSES position paper. World J Emerg Surg (2014) 0.85
Therapeutic Effects of Treatment with Anti-TLR2 and Anti-TLR4 Monoclonal Antibodies in Polymicrobial Sepsis. PLoS One (2015) 0.85
Role of human recombinant activated protein C and low dose corticosteroid therapy in sepsis. Indian J Anaesth (2010) 0.83
Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies. Biologics (2009) 0.79
A dream deferred: the rise and fall of recombinant activated protein C. Crit Care (2013) 0.79
Activated protein C in severe acute pancreatitis without sepsis? Not just yet ... Crit Care (2010) 0.79
Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice? Crit Care (2011) 0.78
Editors' comments on a new trial of activated protein C for persistent septic shock. Intensive Care Med (2008) 0.77
Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center. Ther Clin Risk Manag (2013) 0.77
Co-enrollment of critically ill patients into multiple studies: patterns, predictors and consequences. Crit Care (2013) 0.76
Statistical analysis plan of PROWESS SHOCK study. Intensive Care Med (2010) 0.76
Science, medicine and industry: are we getting out of the black hole in sepsis research? Intensive Care Med (2008) 0.75
An update on activated protein C (xigris) in the management of sepsis. P T (2010) 0.75
Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated). Ann Intensive Care (2012) 0.75
Prolonging resuscitation and postponing the death of activated protein C or is it? Intensive Care Med (2009) 0.75
Early PREdiction of Severe Sepsis (ExPRES-Sepsis) study: protocol for an observational derivation study to discover potential leucocyte cell surface biomarkers. BMJ Open (2016) 0.75
Trials in adult critical care that show increased mortality of the new intervention: Inevitable or preventable mishaps? Ann Intensive Care (2016) 0.75
Updates on role of human recombinant activated protein C in patients with sepsis and severe sepsis: Changed scenario after PROWESS SHOCK trial. Indian J Anaesth (2012) 0.75
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med (2001) 46.58
The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med (2003) 32.30
Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med (2001) 27.70
Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ (2003) 18.72
Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med (2007) 10.02
Management of sepsis. N Engl J Med (2006) 9.01
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med (2005) 8.55
Randomized trials stopped early for benefit: a systematic review. JAMA (2005) 8.43
Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet (2007) 5.23
Activated protein C: do more survive? Intensive Care Med (2005) 4.49
Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ (2006) 4.42
Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med (2001) 3.95
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med (2005) 3.85
Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med (2003) 3.39
Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med (2004) 3.30
Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization. Control Clin Trials (2003) 3.23
Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med (2007) 2.79
Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med (2007) 2.68
Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis. Crit Care Med (2004) 2.48
Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med (2002) 2.47
Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med (2006) 2.32
Severe sepsis epidemiology: sampling, selection, and society. Crit Care (2004) 2.28
Assessing the use of activated protein C in the treatment of severe sepsis. N Engl J Med (2002) 2.22
Ethical issues in stopping randomized trials early because of apparent benefit. Ann Intern Med (2007) 2.21
The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med (1995) 1.99
Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med (2007) 1.85
When (not) to stop a clinical trial for benefit. JAMA (2005) 1.69
Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis? Crit Care (2006) 1.61
Activated protein C (Xigris) treatment in sepsis: a drug in trouble. Acta Anaesthesiol Scand (2006) 1.49
The outcome of patients with sepsis and septic shock presenting to emergency departments in Australia and New Zealand. Crit Care Resusc (2007) 1.39
Severe sepsis--a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med (2001) 1.33
Management of sepsis. BMJ (2007) 1.08
Can we RESOLVE the treatment of sepsis? Lancet (2007) 1.03
Prescription of rh-APC differs substantially among western European countries. Intensive Care Med (2006) 0.98
The Surviving Sepsis guidelines: evidence-based ... or evidence-biased? Crit Care Resusc (2006) 0.97
Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev (2007) 0.85
Use of drotrecogin alfa (activated) for severe sepsis in New Jersey acute care hospitals. Am J Health Syst Pharm (2006) 0.84
Use of recombinant human activated protein C in patients with severe sepsis: a French retrospective multicentre study. Intensive Care Med (2008) 0.83
Drotrecogin alfa (activated) in sepsis: initial experience with patient selection, cost, and clinical outcomes. J Intensive Care Med (2005) 0.83
Management of sepsis. N Engl J Med (2007) 0.83
Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med (2000) 48.03
Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med (2013) 39.56
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med (2008) 31.57
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med (2003) 28.68
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med (2004) 24.47
Acute respiratory distress syndrome: the Berlin Definition. JAMA (2012) 21.04
Comparison of two fluid-management strategies in acute lung injury. N Engl J Med (2006) 19.54
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med (2013) 17.37
Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med (2008) 14.40
Sepsis in European intensive care units: results of the SOAP study. Crit Care Med (2006) 11.78
Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med (2004) 11.78
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med (2003) 10.39
Mortality after surgery in Europe: a 7 day cohort study. Lancet (2012) 9.96
Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med (2006) 9.52
Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med (2012) 9.19
Lung recruitment in patients with the acute respiratory distress syndrome. N Engl J Med (2006) 8.64
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med (2007) 8.33
Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med (2006) 7.97
The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med (2010) 6.69
Tidal hyperinflation during low tidal volume ventilation in acute respiratory distress syndrome. Am J Respir Crit Care Med (2006) 6.22
Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Crit Care Med (2005) 5.76
Sepsis definitions: time for change. Lancet (2013) 5.63
No surgical innovation without evaluation: the IDEAL recommendations. Lancet (2009) 5.57
Transfusion requirements in surgical oncology patients: a prospective, randomized controlled trial. Anesthesiology (2015) 5.52
Ventilator-induced lung injury. N Engl J Med (2013) 5.40
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
Randomized, placebo-controlled clinical trial of an aerosolized β₂-agonist for treatment of acute lung injury. Am J Respir Crit Care Med (2011) 5.24
Extracorporeal Co2 removal in hypercapnic patients at risk of noninvasive ventilation failure: a matched cohort study with historical control. Crit Care Med (2015) 5.22
Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion. Crit Care Med (2005) 5.16
Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA (2011) 5.08
Physiological effects of an open lung ventilatory strategy titrated on elastance-derived end-inspiratory transpulmonary pressure: study in a pig model*. Crit Care Med (2012) 4.71
Initial trophic vs full enteral feeding in patients with acute lung injury: the EDEN randomized trial. JAMA (2012) 4.67
The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med (2010) 4.64
Incidence and prognosis of intraabdominal hypertension in a mixed population of critically ill patients: a multiple-center epidemiological study. Crit Care Med (2005) 4.61
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med (2004) 4.56
A systematic review and meta-analysis on the use of preemptive hemodynamic intervention to improve postoperative outcomes in moderate and high-risk surgical patients. Anesth Analg (2010) 4.29
Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, controlled trial [ISRCTN38797445]. Crit Care (2005) 4.14
Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis (2012) 4.07
DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis (2014) 3.99
Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. Crit Care Med (2009) 3.81
Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med (2008) 3.67
Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med (2004) 3.61
High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest (2005) 3.58
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
The role of open-lung biopsy in ARDS. Chest (2004) 3.46
Making the case for a paradigm shift in trauma surgery. J Am Coll Surg (2006) 3.42
Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med (2014) 3.39
Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med (2014) 3.37
Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med (2007) 3.31
Identification and characterisation of the high-risk surgical population in the United Kingdom. Crit Care (2006) 3.30
Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med (2008) 3.28
Predicting mortality risk in patients undergoing venovenous ECMO for ARDS due to influenza A (H1N1) pneumonia: the ECMOnet score. Intensive Care Med (2012) 3.24
Early vs late tracheotomy for prevention of pneumonia in mechanically ventilated adult ICU patients: a randomized controlled trial. JAMA (2010) 3.20
Continuous positive airway pressure for treatment of postoperative hypoxemia: a randomized controlled trial. JAMA (2005) 3.19
The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med (2012) 3.18
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med (2003) 3.18
Successful cardiopulmonary resuscitation after cardiac arrest as a "sepsis-like" syndrome. Circulation (2002) 3.16
Evaluation and stages of surgical innovations. Lancet (2009) 3.04
Challenges in end-of-life care in the ICU: statement of the 5th International Consensus Conference in Critical Care: Brussels, Belgium, April 2003: executive summary. Crit Care Med (2004) 2.95
Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest (2006) 2.93
Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy. Kidney Int (2008) 2.92
Tidal volume lower than 6 ml/kg enhances lung protection: role of extracorporeal carbon dioxide removal. Anesthesiology (2009) 2.91
Challenges in evaluating surgical innovation. Lancet (2009) 2.86
Ten reasons why we should NOT use severity scores as entry criteria for clinical trials or in our treatment decisions. Crit Care Med (2010) 2.83
Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study. Crit Care Med (2015) 2.81
Trauma-associated lung injury differs clinically and biologically from acute lung injury due to other clinical disorders. Crit Care Med (2007) 2.79
Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial. JAMA (2010) 2.77
Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One (2012) 2.75
The adult respiratory distress syndrome cognitive outcomes study: long-term neuropsychological function in survivors of acute lung injury. Am J Respir Crit Care Med (2012) 2.72
Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest (2004) 2.72
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
Lateralized cognitive processes and lateralized task control in the human brain. Science (2003) 2.62
Higher urine nitric oxide is associated with improved outcomes in patients with acute lung injury. Am J Respir Crit Care Med (2006) 2.61
Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute kidney injury and associated outcomes. Crit Care Med (2011) 2.55
Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study. Ann Surg (2007) 2.55
Influence of overweight on ICU mortality: a prospective study. Chest (2004) 2.54
Age of transfused blood in critically ill adults. N Engl J Med (2015) 2.52
ECMO criteria for influenza A (H1N1)-associated ARDS: role of transpulmonary pressure. Intensive Care Med (2012) 2.50
Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med (2004) 2.49
Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med (2006) 2.47
Perspectives on endothelial-to-mesenchymal transition: potential contribution to vascular remodeling in chronic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2007) 2.46
Alcohol dependence is independently associated with sepsis, septic shock, and hospital mortality among adult intensive care unit patients. Crit Care Med (2007) 2.42